RaQualia Pharma, Inc. (RaQualia), was established in February 2008 and was listed on the JASDAQ Growth Market in July 2011. We would like to express our sincere thanks to all our stakeholders for their support.

RaQualia emerged as a new company from Pfizer's Research Laboratories in Nagoya, Japan. In 2007, Pfizer made the decision to close the Laboratories as part of its effort to restructure global research and development operations. Dr. Atsushi Nagahisa, the Director of Nagoya Laboratories, and a group of fellow scientists and employees created an independent and entirely new drug discovery company, RaQualia.

RaQualia is an R&D-focused pharma company seeking to create new therapies by leveraging the latest science and technology for patients with unmet medical needs. RaQualia's business model is to discover and license development compounds to pharma partners, who will conduct later-stage development and deliver innovative new medicines to patients.

RaQualia's corporate vision is to "bring people health and happiness through innovative new medicines." RaQualia endeavors to discover and deliver safe, new drugs to patients throughout the world.